Brief: Matinas Biopharma Holdings Q2 Loss Per Share $0.03

Matinas BioPharma Holdings

13/08/2019 12:37

Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA REPORTS SECOND QUARTER 2019 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
    * Q2 LOSS PER SHARE $0.03
    * Q2 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES
DATA
    * ADDITIONAL HEAD TO HEAD DATA VERSUS. VASCEPA® EXPECTED IN
2020
    * MATINAS BIOPHARMA HOLDINGS - CASH AND CASH EQUIVALENTS AT
JUNE
30, 2019 WERE APPROXIMATELY $36.8 MILLION, COMPARED TO $12.4
MILLION AT DECEMBER 31, 2018
    * NIH-FUNDED PHASE 1/2 ENACT TRIAL OF MAT2203 IN
CRYPTOCOCCAL
MENINGITIS TO COMMENCE IN Q4 2019
    * ON TRACK TO COMMENCE A COMPARATIVE CLINICAL BRIDGING
BIOAVAILABILITY STUDY IN Q4 2019, EXPECTED COMPLETION IN Q1 2020

Source text for Eikon:  ID:nGNX3wsYyr 
Further company coverage:  MTNB.A